Corcept Therapeutics (CORT) Cash & Current Investments (2010 - 2026)

Corcept Therapeutics has disclosed Cash & Current Investments across 17 years of filings, most recently posting $338.2 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $338.2 million, up 4.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $338.2 million (up 4.78% YoY), and the FY2025 annual result was $372.2 million, down 2.92% from the prior year.
• Cash & Current Investments came in at $338.2 million for Q1 2026 at Corcept Therapeutics, down from $372.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $473.2 million in Q2 2024 to a low of $322.8 million in Q1 2025.
• The 5-year median for Cash & Current Investments is $372.2 million (2025), against an average of $384.7 million.
• Across the five-year window, Cash & Current Investments surged 93.11% in 2022 and slipped 27.67% in 2025, its largest moves.
• Corcept Therapeutics' Cash & Current Investments stood at $431.7 million in 2022, then declined by 14.7% to $368.2 million in 2023, then advanced by 4.1% to $383.3 million in 2024, then fell by 2.92% to $372.2 million in 2025, then fell by 9.13% to $338.2 million in 2026.
• The last three Cash & Current Investments figures came in at $338.2 million (Q1 2026), $372.2 million (Q4 2025), and $421.7 million (Q3 2025), per Business Quant data.